Filing Flows › Halozyme Therapeutics (HALO) › Q3 2026 › vs Q2 2026
Halozyme Therapeutics (HALO) Q3 2026 vs Q2 2026 (quarter over quarter)
Halozyme Therapeutics's revenue rose $12.0M (+2%) from $481M in Q2 2026 to $493M in Q3 2026. Operating margin 59.8% against 59.8% (+0.0 pts).
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 59.8% | 59.8% | +0.0 pts |
| Net margin | 50.1% | 47.8% | +2.3 pts |
| Free cash flow margin | 51.8% | 49.2% | +2.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $493M | $481M | $12.0M | +2% |
| Operating profit | $295M | $288M | $7.3M | +3% |
| Costs & expenses | $198M | $193M | $4.7M | +2% |
| Pre-tax earnings | $291M | $285M | $5.7M | +2% |
| Other expense, net | $4.3M | $2.8M | $1.6M | +58% |
| Cost of revenue | $82.5M | $79.2M | $3.3M | +4% |
| Research & development | $27.8M | $27.7M | $114K | +0.4% |
| SG&A | $58.2M | $57.0M | $1.2M | +2% |
| Other operating costs | $29.5M | $29.5M | $0 | 0% |
| Net earnings | $247M | $230M | $17.1M | +7% |
| Income tax | $43.6M | $55.0M | −$11.4M | -21% |
| Depreciation & amortization | $4.7M | $4.5M | $200K | +4% |
| Share-based compensation | $16.8M | $17.7M | −$896K | -5% |
| Working capital & other | $10.3M | $11.2M | −$937K | -8% |
| Operating cash flow | $258M | $241M | $17.4M | +7% |
| Free cash flow (OCF − capex) | $255M | $237M | $18.5M | +8% |
| Capital expenditures | $3.0M | $4.2M | −$1.1M | -27% |
Questions
How much did Halozyme Therapeutics's revenue grow quarter over quarter in Q3 2026?
Halozyme Therapeutics's revenue rose $12.0M (+2%) from $481M in Q2 2026 to $493M in Q3 2026. Operating margin 59.8% against 59.8% (+0.0 pts).